文献速递眼底病与葡萄膜炎

每月给药与治疗并延长方案雷珠单抗治疗新生血管性年龄相关性黄斑变性黄斑萎缩的比较:TREX-AMD试验结果

Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
PubMed 文献 · Ophthalmology · 2016-11-15

这项18个月多中心随机对照试验纳入60例单眼初治新生血管性AMD患者,按1:2随机接受每月或TREX方案雷珠单抗治疗,比较黄斑萎缩扩大率。最终分析88眼(每月组19眼、TREX组30眼、对侧对照39眼),18个月平均黄斑萎缩扩大率三组间无显著差异(P=0.12)。基线中心凹脉络膜厚度、视网膜下高反射物质厚度和出血是新发黄斑萎缩的显著预测因素。

要点

  • 每月组、TREX组和对侧对照眼18个月平均黄斑萎缩扩大率分别为0.39±0.67、1.1±1.9和0.49±1 mm²,三组间无显著差异(P=0.12)。
  • 基线存在黄斑萎缩的40.9%(36例)患者中,三组平均黄斑萎缩扩大率分别为0.9±1、1.9±2.2和1±1.3 mm²(P=0.31)。
  • 基线中心凹脉络膜厚度(127±46 vs. 155±55 μm,P=0.01)和视网膜下高反射物质厚度(106±131 vs. 50±85 μm,P=0.02)与黄斑萎缩显著相关。

核心结论

  • 雷珠单抗无论每月给药还是按TREX方案给药,对新生血管性AMD眼新发黄斑萎缩均未显示统计学显著影响。
  • 基线中心凹脉络膜厚度、视网膜下高反射物质厚度和出血均为新发黄斑萎缩的显著预测因素。

研究设计与样本

  • 18个月、多中心、随机、对照临床试验。
  • 60例单眼初治新生血管性AMD患者按1:2随机接受每月或TREX方案雷珠单抗治疗。
  • 最终分析队列包括88眼:每月组19眼、TREX组30眼、对侧对照眼39眼。
  • 使用谱域光学相干断层扫描(SD OCT)和眼底自发荧光(FAF)成像随访18个月,黄斑萎缩通过Heidelberg Region Finder软件在FAF图像上定量。

主要发现

  • 18个月平均黄斑萎缩扩大率:每月组0.39±0.67 mm²、TREX组1.1±1.9 mm²、对侧对照眼0.49±1 mm²(P=0.12)。
  • 基线存在黄斑萎缩的40.9%(n=36)患者中,三组平均黄斑萎缩扩大率分别为0.9±1、1.9±2.2和1±1.3 mm²(P=0.31)。
  • 三组黄斑萎缩发生率分别为40%、0%和8.3%。
  • Mann-Whitney U检验显示基线中心凹脉络膜厚度(127±46 vs. 155±55 μm,P=0.01)和视网膜下高反射物质厚度(106±131 vs. 50±85 μm,P=0.02)与黄斑萎缩显著相关。
  • 无基线黄斑萎缩眼中,视网膜下高反射物质存在、视网膜下高反射物质厚度、色素上皮脱离厚度和基线出血存在均为新发黄斑萎缩的显著预测因素(P=0.04、0.01、0.04、0.004、0.01)。

关键数值与推荐

  • 18个月平均黄斑萎缩扩大率三组间无显著差异(P=0.12)。
  • 基线存在黄斑萎缩患者中,三组平均黄斑萎缩扩大率无显著差异(P=0.31)。
  • 基线中心凹脉络膜厚度与黄斑萎缩显著相关(P=0.01)。
  • 基线视网膜下高反射物质厚度与黄斑萎缩显著相关(P=0.02)。
  • 无基线黄斑萎缩眼中,视网膜下高反射物质存在、视网膜下高反射物质厚度、色素上皮脱离厚度和基线出血存在均为新发黄斑萎缩的显著预测因素(P=0.04、0.01、0.04、0.004、0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the enlargement rate of macular atrophy (ERMA) in eyes treated with ranibizumab monthly or using a treat-and-extend (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control eyes, as well as analyze risk factors for macular atrophy (MA) development and progression. DESIGN: Eighteen-month, multicenter, randomized, controlled clinical trial. PARTICIPANTS: Sixty patients with treatment-naïve neovascular AMD in 1 eye randomized 1:2 to monthly or TREX ranibizumab. METHODS: Patients' study and fellow eyes were followed for 18 months using spectral-domain optical coherence tomography (SD OCT) and fundus autofluorescence (FAF) imaging. The MA was quantified on FAF images using Heidelberg Region Finder software (Heidelberg Engineering, Heidelberg, Germany), with suspected areas of atrophy confirmed by SD OCT and infrared reflectance imaging. For eyes without baseline MA yet developed MA by 18 months, intervening visits were assessed to determine the first visit at which MA appeared to define progression rates. Foveal choroidal thickness (FCT), subretinal hyperreflective material (SHRM), and pigment epithelial detachment (PED), were assessed at baseline to determine whether they influenced MA progression. MAIN OUTCOME MEASURES: Mean ERMA at 18 months. Relationship between visual acuity and MA, and the baseline risk factors for ERMA were also assessed. RESULTS: The final analysis cohort included 88 eyes in 3 groups: monthly (n = 19), TREX (n = 30), and control fellow eyes (n = 39). Mean ERMA over 18 months was 0.39±0.67 (monthly), 1.1±1.9 (TREX), and 0.49±1 mm2 (control, P = 0.12). Mean ERMA per group among the 40.9% (n = 36) of baseline patients with MA was 0.9±1, 1.9±2.2, and 1±1.3 mm2, respectively (P = 0.31). The incidence rate of MA in the 3 groups was 40%, 0%, and 8.3%, respectively. Mann-Whitney U test revealed a statistically significant association between baseline FCT (127±46 vs. 155±55 μm, P = 0.01) and SHRM thickness (106±131 vs. 50±85 μm, P = 0.02) on MA. In eyes with no baseline MA, presence of SHRM, SHRM, and PED thickness, and presence of baseline hemorrhage were all significant predictors of new MA development (P = 0.04, 0.01, 0.04, 0.004, 0.01, respectively). CONCLUSIONS: Ranibizumab did not show a statistically significant influence on new MA development in eyes with neovascular AMD, whether dosed monthly or per TREX regimen. The FCT, SHRM thickness, and hemorrhage at baseline were all significant predictors of new MA.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Abdelfattah NS, Al-Sheikh M, Pitetta S, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2016. PMID: 27863845. doi:10.1016/j.ophtha.2016.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。